Ana Hernández-García

Ana Hernández-García

Auto-generated profile, based on publicly available information

Ana Hernández-García


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
JRJorge Rodríguez
Jorge Rodríguez
RARosa Andreu
Rosa Andreu
RDRoberto Daza
Roberto Daza
LFLucía Fernández-Arroyo
Lucía Fernández-Arroyo
AHAna Hernández-García
Ana Hernández-García
MCMaría J. Calzada
María J. Calzada
In chronic respiratory diseases (CRDs), oxidative stress and inflammation are closely linked, driving disease onset, progression, and comorbidities. Oxidative stress activates inflammatory pathways, while chronic inflammation promotes further reactive oxygen species (ROS) production, creating a vicious cycle leading to airway remodeling, reduced lung function, and exacerbations. This review highlights the central roles of inflammation and oxidative stress in chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). In COPD, chronic hypoxemia associates with emphysema, appearing with disease progression. In OSA, beyond systemic consequences, pulmonary inflammation and oxidative stress contribute to lung injury as well. Although COPD and OSA are distinct conditions, some patients present with “overlap syndrome”, a term used in this review to describe the coexistence of both. This combination poses unique diagnostic and therapeutic challenges. We also examine the role of hypoxia and its transcriptional effects via hypoxia-inducible factors (HIFs) in promoting oxidative stress and inflammation. Finally, we explore how artificial intelligence (AI) offers promising tools to improve diagnosis, monitoring, and management of CRDs and may help elucidate mechanistic links between hypoxia, inflammation, and oxidative stress, contributing to more personalized therapeutic strategies.

10 June 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
JRJorge Rodríguez
Jorge Rodríguez
RARosa Andreu
Rosa Andreu
LSLeila Pérez Sánchez
Leila Pérez Sánchez
AHAna Hernández-García
Ana Hernández-García
CMCecilia Muñoz-Calleja
Cecilia Muñoz-Calleja
MCMaría J. Calzada
María J. Calzada
Chronic obstructive pulmonary disease (COPD), whose main risk factor is cigarette smoking, is among the most prevalent diseases worldwide. Previous studies have shown that cigarette smoke extract (CSE) can directly affect pulmonary artery function independently of hypoxia resulting from the airway obstruction. In addition, CSE also affects bronchial smooth muscle, leading to airway hyper-responsiveness. However, its specific impact on the contractile machinery of this compartment remains unclear. In this study, using in vitro experiments with human bronchial smooth muscle cells (hBSMCs), we found that CSE exposure disrupted calcium homeostasis, increased ROS and lipid peroxidation, and reduced cell antioxidant defenses. Furthermore, CSE exposure altered the cell contractile apparatus by decreasing key cytoskeletal proteins and impairing actin dynamics, potentially contributing to the dysregulated contractile response of cells. Notably, these effects were significantly attenuated by antioxidant drugs such as mitoTEMPO and N-acetylcysteine, as well as by the inhibition of the endoplasmic reticulum (ER) calcium channels with 2-aminoethoxydiphenyl borate (2-APB). More importantly, mitoTEMPO partially restored the contractile response of bronchus upon CSE challenge. Collectively, our findings give evidence that CSE-mediated increase in ROS and intracellular calcium contribute to cytoskeletal disruption and functional impairment in airway smooth muscle. Moreover, these results also point to potential therapeutical approaches for mitigating the harmful effects of cigarette smoke in the lung.

17 February 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MVMarta Villegas-Esguevillas
Marta Villegas-Esguevillas
BBBianca Barreira
Bianca Barreira
AHAna Hernández-García
Ana Hernández-García
RARui Adão
Rui Adão
DCDaniel Morales Cano
Daniel Morales Cano
ACAngel Cogolludo
Angel Cogolludo
Sigma-1 receptors (S1R) are potential pharmacological targets for neurodegenerative diseases and cardiac pathologies, such as cardiac hypertrophy. S1R modulate several cellular functions by interacting with various proteins, including ion channels. Pulmonary arterial hypertension (PAH) is a severe disease characterised by exacerbated pulmonary vasoconstriction and pathological remodelling of the pulmonary vasculature, leading to right ventricular (RV) hypertrophy and eventual heart failure. Herein, we evaluated the therapeutic potential of the S1R agonist PRE084 in the hypoxia plus SU5416 (Hpx/Su) rat model of severe PAH. We found that treatment with PRE084 significantly improved the attenuated activity of KV1.5 channels, reduced hypertrophy, and restored the resting membrane potential to physiological levels in pulmonary artery smooth muscle cells from Hpx/Su animals. This is associated with attenuated pulmonary vasoconstriction. Treatment with PRE084 also improved endothelium-dependent relaxation and attenuated pulmonary vascular remodelling in Hpx/Su rats. Notably, PRE084 ameliorated RV systolic pressure, RV dysfunction, hypertrophy, and fibrosis in Hpx/Su rats, as assessed through haemodynamic, echocardiographic, and histological evaluations. These effects were associated with the normalization of p-Akt expression and inositol levels in the RV. In summary, PRE084 markedly improved both the functional and morphological parameters characteristic of PAH, thereby attenuating disease progression. Collectively, our study suggests that targeting S1R may represent a promising therapeutic approach for the treatment of PAH.

15 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JRJorge Rodríguez
Jorge Rodríguez
RARosa Andreu
Rosa Andreu
LSLeila Pérez Sánchez
Leila Pérez Sánchez
AHAna Hernández-García
Ana Hernández-García
CMCecilia Muñoz-Calleja
Cecilia Muñoz-Calleja
MCMaría J. Calzada
María J. Calzada
Chronic obstructive pulmonary disease (COPD), whose main risk factor is cigarette smoking, is among the most prevalent diseases worldwide. Previous studies have shown that cigarette smoke extract (CSE) can directly affect pulmonary artery function independently of hypoxia resulting from the airway obstruction. In addition, CSE also affects bronchial smooth muscle, leading to airway hyper-responsiveness. However, its specific impact on the contractile machinery of this compartment remains unclear. In this study, using in vitro experiments with human bronchial smooth muscle cells (hBSMC) we found that CSE exposure disrupted calcium homeostasis, increased ROS and lipid peroxidation, and reduced cell antioxidant defenses. Furthermore, CSE exposure altered the cell contractile apparatus by decreasing key cytoskeletal proteins and impairing actin dynamics, this potentially contributing to cell dysregulated contractile response. Notably, these effects were significantly attenuated by antioxidant drugs such as mitoTEMPO and N-acetylcysteine, as well as by the inhibition of the RE calcium channels with 2-aminoethoxydiphenyl borate (2-APB). More importantly, mitoTEMPO partially restored the contractile response of bronchus upon CSE challenge. Collectively, our findings give evidence that CSE-mediated increase in ROS and intracellular calcium contribute to cytoskeletal disruption and functional impairment in airway smooth muscle. Moreover, these results also point to potential therapeutical approaches for mitigating the harmful effects of cigarette smoke in the lung.

31 October 2026 in European Journal of Pharmacology
Verified
Journal Article
Open access
MVMarta Villegas-Esguevillas
Marta Villegas-Esguevillas
BBBianca Barreira
Bianca Barreira
AHAna Hernández-García
Ana Hernández-García
LGLaura Juan-José Gibello
Laura Juan-José Gibello
DCDaniel Morales Cano
Daniel Morales Cano
ACAngel Cogolludo
Angel Cogolludo

Verified
Journal Article
Open access
PDF file
DCDaniel Morales Cano
Daniel Morales Cano
SMSandra Medrano-Garcia
Sandra Medrano-Garcia
BBBianca Barreira
Bianca Barreira
AHAna Hernández-García
Ana Hernández-García
RKRahul Kumar
Rahul Kumar
EFEdgar Fernández-Malavé
Edgar Fernández-Malavé
Local immune cell activation and vascular remodelling are characteristic pathogenic features of pulmonary arterial hypertension (PAH). HIV and schistosome infections have been individually associated with PAH. However, whether co-infection with these pathogens has a distinct impact on the development of pulmonary vascular disease remains poorly understood, partly due to the lack of experimental animal models. In a novel non-infectious model of HIV and Schistosoma pulmonary co-exposure based on lung embolisation of S. mansoni eggs in HIV-transgenic (HIV) mice, we previously reported exacerbated endothelial remodelling and dysfunction, along with increased pulmonary arterial pressure; which were associated with a unique profile of pro-inflammatory cytokines in the lung. In the present study, we used flow cytometric analysis of isolated lung leukocytes and immunofluorescence staining to characterise the pulmonary immune cell landscape associated with individual or combined exposure to HIV and schistosome. Compared with mice exposed to HIV (untreated HIV mice) or schistosome (egg-treated wild-type mice), co-exposed (egg-treated HIV mice) animals showed significantly increased numbers of interstitial and alveolar macrophages, patrolling-type monocytes, NKT and γδ T cells, and reduced CD8+ αβ T cells. Other lung immune cells, including inflammatory-type monocytes, eosinophils/neutrophils, dendritic cells, CD4+ αβ T cells, NK cells and B cells were not significantly affected in the co-exposure condition. Taken together, these results show for the first time that combined pulmonary exposure to HIV and Schistosoma, as it may occur in co-infected individuals, alters the local immune cell landscape in a manner distinct from that of individual exposure. Furthermore, these findings may contribute to a better understanding of the complex inflammatory processes involved in the pathogenesis of PAH, thereby supporting the development of therapies targeting pathogenic immune cells in pulmonary vascular disease associated with HIV and Schistosoma co-morbidity.